Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2016-10-27 Capital/Financing Update
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus Supplement' and references a registration statement filed with the SEC under Rule 424(b)(5). It details an offering of 5,000,000 shares of common stock by Collegium Pharmaceutical, Inc., including pricing, underwriting discounts, and use of proceeds. The text includes typical prospectus content such as risk factors, use of proceeds, dividend policy, capitalization, dilution, and legal matters. There is no indication of financial statements or management discussion of financial results, nor is it an earnings release or annual report. The document is a detailed offering prospectus supplement related to a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual offering document.
2016-10-27 English
424B5
Capital/Financing Update Classification · 100% confidence The document is titled as a "Preliminary Prospectus Supplement" and references a registration statement on Form S-3 filed with the SEC. It discusses an offering of common stock, underwriting discounts, use of proceeds, risk factors, and other details typical of a securities offering document. The text includes disclaimers about the offer not being complete and not constituting an offer to sell in certain jurisdictions. It also references the Securities Act of 1933 and SEC rules, indicating it is a filing related to capital raising. There is no indication of financial statements or earnings data, nor is it an annual or quarterly report. The document is clearly a prospectus supplement related to a capital raising event, which fits the category of Capital/Financing Update (CAP).
2016-10-25 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 25, 2016, by Collegium Pharmaceutical, Inc. It includes disclosures about the commencement of an underwritten public offering of common stock, preliminary financial estimates for the quarter ended September 30, 2016, and updates on the company's operations and product developments. The document references prior filings such as the Annual Report on Form 10-K for the year ended December 31, 2015, and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, but does not itself contain comprehensive financial statements or detailed financial analysis. The primary focus is on the announcement of the public offering and related financial condition updates, which aligns with capital raising activities. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (13,186 characters) and content confirm it is not a brief announcement or a certification, but a substantive current report on financing activities.
2016-10-25 English
Regulatory Filings 2016
Regulatory Filings
2016-10-19 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Collegium Pharmaceutical, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a correspondence related to a securities registration process, specifically requesting the SEC to declare the registration statement effective earlier. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory correspondence related to a capital raising registration statement but is not itself a financing update or capital structure change announcement. Given the nature of the document as a formal regulatory correspondence and the absence of substantive financial data or report content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents and correspondence that do not fit other categories.
2016-10-14 English
Regulatory Filings 2016
Regulatory Filings
2016-10-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.